The Broad Institute, Inc.;Dana-Farber Cancer Institute, Inc.;Bayer Pharma AG
发明人:
申请号：
EP16836014.7
公开号：
EP3334404A4
申请日:
2016.08.12
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
